anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Selective inhibitors for COX-2 were discovered to prevent the reactivation of viruses that cause latent infections such as herpes simplex virus (HSV-1 and HSV-2). Using mice with a latent infection of HSV, which is subject to reactivation when heat-stressed, a selective COX-2 inhibitor (celecoxib) was shown to significantly suppress viral reactivation in the eye when the inhibitor was administered either by intraperitoneal injection or orally. Acetylsalicylic acid, a nonspecific cyclooxygenase inhibitor, was also found to suppress viral reactivation in the heat-stressed mouse model. The COX-2 specific inhibitor, celecoxib, was more effective in preventing viral recurrence than was the nonspecific cyclooxygenase inhibitor aspirin. The use of selective inhibitors of COX-2 to inhibit the recurrence of latent viral infections will be more effective and have fewer side effects than the nonspecific inhibitors. In addition, selective inhibitors of COX-2 can be combined with other antiviral compounds.
The renin-angiotensin-aldosterone (RAAS) system plays a significant role in renal and cardiovascular pathophysiology, since its increased activity is involved in arterial hypertension, heart failure, and kidney disease. ACEIs and ARBs are essential drugs for nephroprotection: they reduce blood pressure values and albuminuria, both related to cardiovascular damage and CKD progression. The nephroprotective effects are evident in both diabetes mellitus and non-diabetic renal disease, and the initial eGFR fall, if not more than 30%, should be considered as a marker of long-term success of renal protection. To optimize the RAAS inhibition salt intake should be strictly controlled, moreover the effective antiproteinuric dose can often be higher than that used as an antihypertensive. In selected and closely monitored cases, it is also possible to consider dual RAAS blockade. Finally, it should be noted that in patients with advanced CKD RAAS inhibition should not be discontinued, either because it does not give any benefit on GFR or because it increases cardiovascular risk.
FIELD: medicine. SUBSTANCE: one should daily introduce antibacterial preparation in combination with serumal preparation. Moreover, as antibacterial preparation one should apply antibiotics of wide spectrum of action and as serumal one - F(ab) 2 -fragment of antianthrax immunoglobulin antibodies and, additionally, immunomodulator. Moreover, antibiotic is daily introduced in daily dosage being equivalent to man-dose, and F(ab) 2 -fragment of antianthrax immunoglobulin antibodies is injected daily intravenously in daily dose being equivalent to man-dose, and as immunomodulator polyoxidonium is daily applied in daily dose being equivalent to man-dose either intramuscularly or intravenously; all preparations are injected till clinical signs of disease disappear. EFFECT: higher efficiency and safety of therapy. 3 tbl
The patient receives the standard therapy plus an additional volume of saline solution equivalent to the amount of von Willebrand factor concentrate (vWFC) the patient would receive in Group W to keep the blind. The volume is given according to the VWFC-solution (0.25 ml/kg BW) what would be resulting from the patient's weight followed by a continuous saline infusion (0.50 ml/kg BW) until the weaning from ECMO is completed or if ECMO is needed longer than 7 days, the Investigational Medicinal Product (IMP) administration is stopped on the 7th day.
This is an open-label, multicenter, single arm study. This study consists of three parts: the Pretreatment Period, the Treatment Period, and the Follow-up Period. Subjects who meet all of eligibility criteria by the screening examination will be enrolled into the study, and start treatment with mogamulizumab within 30 days after obtaining consent. Mogamulizumab will be administered at the dose of 1.0 mg/kg as an intravenous (iv) infusion over at least 1 hour on Days 1, 8, 15, and 22 of Cycle 1 and on Days 1 and 15 of subsequent cycles. Each treatment cycle is set as 28 days. Subjects will continue the treatment of mogamulizumab until any of the criteria for study withdrawal is met. After stopping treatment, the end-of treatment examination will be conducted within 30 days after the last dose.The primary efficacy analysis will be conducted once all subjects terminate treatment by the confirmation of PD/drug intolerance/unacceptable toxicity or 12 months after the date of the first mogamulizumab administration of the last subject of entire study, whichever comes first.
To date, the SARS-CoV-2 pandemic still represents a great clinical challenge worldwide, and effective anti-COVID-19 drugs are limited. For this reason, nutritional supplements have been investigated as adjuvant therapeutic approaches in disease management. Among such supplements, vitamin D has gained great interest, due to its immunomodulatory and anti-inflammatory actions both in adult and pediatric populations. Even if there is conflicting evidence about its prevention and/or mitigation effectiveness in SARS-CoV-2 infection, several studies demonstrated a strict correlation between hypovitaminosis D and disease severity in acute COVID-19 and MIS-C (multisystem inflammatory syndrome in children). This narrative review offers a resume of the state of the art about vitamin D's role in immunity and its clinical use in the context of the current pandemic, specially focusing on pediatric manifestations and MIS-C. It seems biologically reasonable that interventions aimed at normalizing circulating vitamin D levels could be beneficial. To help clinicians in establishing the correct prophylaxis and/or supportive therapy with vitamin D, well-designed and adequately statistically powered clinical trials involving both adult and pediatric populations are needed. Moreover, this review will also discuss the few other nutraceuticals evaluated in this context.
BACKGROUND: PDGFRB fusions in acute lymphoblastic leukemia (ALL) is rare. The authors identified 28 pediatric PDGFRB-positive ALL. They analyzed the features, outcomes, and prognostic factors of this disease.
METHODS: This multicenter, retrospective study included 6457 pediatric patients with newly diagnosed PDGFRB fusion ALL according to the CCCG-ALL-2015 and CCCG-ALL-2020 protocols from April 2015 to April 2022 in 20 hospitals in China. Of these patients, 3451 were screened for PDGFRB fusions.
RESULTS: Pediatric PDGFRB-positive ALL accounted for only 0.8% of the 3451 cases tested for PDGFRB. These patients included 21 males and seven females and 24 B-ALL and 4 T-ALL; the median age was 10 years; and the median leukocyte count was 29.8 × 109/L at baseline. Only one patient had eosinophilia. Three patients had an IKZF1 deletion, three had chromosome 5q31-33 abnormalities, and one suffered from a complex karyotype. The 3-year event-free survival (EFS), overall survival (OS), and cumulative incidence of relapse (CIR) were 33.1%, 65.5%, and 32.1%, respectively, with a median follow-up of 25.5 months. Twenty patients were treated with chemotherapy plus tyrosine-kinase inhibitors (TKIs) and eight were treated without TKI. Complete remission (CR) rates of them were 90.0% and 63.6%, respectively, but no differences in EFS, OS, or CIR. Univariate analyses showed patients with IKZF1 deletion or measurable residual disease (MRD) ≥0.01% after induction had inferior outcomes (p < .05).
CONCLUSIONS: Pediatric PDGFRB-positive ALL has a poor outcome associated with high-risk features. Chemotherapy plus TKIs can improve the CR rate, providing an opportunity for lower MRD levels and transplantation. MRD ≥0.01% was a powerful adverse prognostic factor, and stratified treatment based on MRD may improve survival for these patients.
PLAIN LANGUAGE SUMMARY: Pediatric acute lymphoblastic leukemia patients with PDGFRB fusions are associated with high-risk clinical features such as older age, high white blood cell count at diagnosis, high measurable residual disease after induction therapy, and increased risk of leukemia relapse. Chemotherapy plus tyrosine-kinase inhibitors can improve the complete remission rate and provide an opportunity for lower measurable residual disease (MRD) levels and transplantation for pediatric PDGFRB-positive acute lymphoblastic leukemia (ALL) patients. The MRD level was also a powerful prognostic factor for pediatric PDGFRB-positive ALL patients.
A method for preparing the complex of ethyl ester of alpha-bromoisovaleric acid, essential oil and cyclodextrin in the solid form comprises mixing the complex with povidon. The components are loaded in the following sequence: purified water and povidon are mixed until dissolution, then cyclodextrin is added and the dispersion is mixed until homogeneity. Ethyl ester of alpha-bromoisovaleric acid and essential oil are dissolved in ethanol as separate solution and mixed until transparency. This solution is added to the dispersion of cyclodextrin and aqueous solution of povidon. The dispersion is mixed until the increase in the viscosity. Finally, the composition is dried in the oven.
Insulin is a hormone secreted by cells β of pancreatic islets in response to increased levels of glucose and serum amino acids. Insulin resistance means a decrease in the ability of insulin to stimulate glucose utilization because is disabled in the insulin receptor, decrease in concentration of receptors or failure mechanism of cell transit. Recently, the discovery of a substance called low molecular weight chromium-binding substance (LMWCr), showed the ability of this substance in amplifying insulin signaling, increasing the sensitivity of insulin receptors in the plasma membrane. This way, the capacity of LMWCr in activating the insulin receptor depends on levels of serum chromium. Thus, the hypothesis that the nutritional status of individual poor chromium contributes to the decrease in glucose tolerance and consequently, for type 2 Diabetes. Thus, it becomes necessary to assess the effect of supplementation of chromium in increased insulin sensitivity in patients with type 2 Diabetes. This is a double-blind randomized clinical trial, consisting of a period of three months of nutritional intervention with chromium nicotinate, biochemical and anthropometric evaluation and assessment of food profile and physical activity.
This group will receive Psychoeducation which is aimed at providing information, resources, and non-specific support related to adapting well to cancer. The education will be provided on a one-on-one basis, for 2 hours once a week for six weeks by a trained therapist with a master's degree in Clinical Psychology.
OBJECTIVE: To determine whether maternal Adverse Childhood Experiences (ACEs) are (a) associated with increased inflammatory gene expression in mother-child dyads and (b) whether a parenting intervention (ATTACH™) moderates the association between maternal ACEs and mother and/or child inflammatory gene expression.
METHODS: Twenty mother-child dyads, recruited from a domestic violence shelter in Calgary, AB, Canada, were randomized into an ATTACH™ parenting intervention group (n = 9) or a wait-list control group (n = 11). Maternal ACEs were assessed. The mothers and children each provided one non-fasting blood sample after the intervention group completed the ATTACH™ program, which was assayed to quantify the Conserved Transcriptional Response to Adversity (CTRA) score, indicating inflammatory gene expression profile. Mixed-effect linear models were used, separately in mothers and children, to examine the associations between CTRA score, maternal ACEs, and the ACEs-by-intervention group interaction term. The covariates were age, sex, ethnicity, and maternal medication use.
RESULTS: Higher maternal ACEs were associated with higher child CTRA scores (b = 0.123 ± SE 0.044, p = 0.005), indicating an increased pro-inflammatory gene expression profile. The ATTACH™ parenting intervention moderated this association between maternal ACEs and child CTRA scores (b = 0.328 ± SE 0.133, p = 0.014). In mothers, the ACEs-by-intervention interaction terms were insignificant (p = 0.305).
CONCLUSIONS: Maternal ACEs could exert an intergenerational impact on child inflammatory activity, and this association could be moderated by participating in the ATTACH™ parenting intervention.
Provided is a biological information calculation system capable of realizing quantitative evaluation relating to the state of a user. The biological information computing system calculates blood information related to blood of a user, and is characterized by comprising an acquisition unit, a database, a calculation unit, and an evaluation unit. The acquisition unit acquires evaluation data based on a pulse wave of a user. The database stores classification information generated by using a plurality of pieces of learning data, which are a pair of input data and reference data, wherein the input data is data based on learning pulse waves acquired in advance, and the reference data is data including blood information associated with the input data. The calculation unit calculates blood information corresponding to the evaluation data with reference to the database. The evaluation unit generates an evaluation result regarding the state of the user based on the blood information.
Nerve Stimulation (electrical stimulation) is randomly chosen using a computer program. Time of placement begins when the catheter-placement first touches the patient. After catheter placement patient is asked their discomfort on a 0-10 scale (0=no discomfort and 10=worst discomfort imaginable) and called the day after surgery by the research staff.
To provide a hydrolyzable cleaning sheet capable of achieving both of high storage stability and suppression of skin irritation.SOLUTION: A cleaning sheet of the present invention comprises an aqueous medicine which is impregnated in a hydrolyzable base material sheet comprising cellulosic fibers and a water soluble binder. The aqueous medicine comprises: 60 mass% or greater and 90 mass% or smaller of water; 5 mass% or greater and 30 mass% or smaller of a water soluble organic solvent selected from a group consisting of polyols and glycol ethers; 0.15 mass% or greater and 1 mass% or smaller of benzoic acids; and 1 mass% or greater and 5 mass% or smaller of a crosslinking agent of the binder, and comprises no paraben. After impregnating the aqueous medicine in the hydrolyzable base material sheet, pH of the aqueous medicine at 25°C is 3 or greater and 5.5 or smaller. The benzoic acids are preferably benzoic acid and metallic salt thereof. The water soluble organic solvent is preferably one of polyols. The aqueous medicine preferably contains no monovalent lower alcohol.SELECTED DRAWING: None
<P>PROBLEM TO BE SOLVED: To provide a microcapsule suitable for therapeutic or diagnostic use.  <P>SOLUTION: The microcapsule has a wall thickness of no more than 500 nm and bulk density of no more than 0.2 g/cm<SP>3</SP>, is aerodynamically light, is suitable for delivery to the lung or for diagnosis by ultrasonic waves, and is especially suitable for formulation with an inspirator. When the microcapsule includes a therapeutic agent, the microcapsule is quickly discharged and then uptaken in lung, absolutely contrastively to any controlled release formulation, thus avoiding drug inclusion. Furthermore, if the microcapsule includes only a wall-forming substance and does not include the therapeutic agent, the microcapsule is especially suitable for ultrasonic wave imaging. The relatively thin wall of the microcapsule exhibits echogenicity improved in appearance.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Participants received SAR245409 50 mg twice daily or at the established dose as combination regimen in the parental study until disease progression, unacceptable toxicity, withdrawal of consent, or until commercial supplies of SAR245409 were available (up to 1917 days). Commercially available drugs were used as combination medications with SAR245409 (depending on the parental study, the following drugs were used in combination with SAR245409: letrozole, temozolomide, rituximab, bendamustine and rituximab).
Amoxicillin and clavulanate potassium extended-release tablets may cause severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP). If patients develop a skin rash, they should be monitored closely, and amoxicillin and clavulanate potassium extended-release tablets discontinued if lesions progress.

###  5.3 Drug-Induced Enterocolitis Syndrome (DIES)

Drug-induced enterocolitis syndrome (DIES) has been reported with the use of amoxicillin, a component of amoxicillin and clavulanate potassium extended-release tablets [see Adverse Reactions (6.2)], with most cases occurring in pediatric patients ≤18 years of age. DIES is a non-IgE mediated hypersensitivity reaction characterized by protracted vomiting occurring 1 to 4 hours after drug ingestion in the absence of skin or respiratory symptoms. DIES may be associated with pallor, lethargy, hypotension, shock, diarrhea within 24 hours after ingesting amoxicillin, and leukocytosis with neutrophilia. If DIES occurs, discontinue amoxicillin and clavulanate potassium extended-release tablets and institute appropriate therapy.
Recent evidence suggests the mechanistic role of mitochondria and oxidative stress in the development of celecoxib-induced cardiotoxicity. On the other, it has reported the positive effects of vitamin D on oxidative stress and the maintenance of mitochondrial functions. This current study examined the cardiac effects of celecoxib, doxorubicin, vitamin D, and a combination of them in rats. The effect of 10 days of celecoxib (100 mg/kg/day), doxorubicin (2.5 mg/kg), vitamin D (60,000 U/kg), and their combination was studied on cardiac function according to serum lactate dehydrogenase (LDH), creatine kinase (CK), glutathione (GSH), and malondialdehyde (MDA) levels as well as mitochondrial succinate dehydrogenases (SDH) activity, reactive oxygen species (ROS) production, mitochondrial swelling, and mitochondrial membrane potential (MMP). Results showed that celecoxib and its combination with doxorubicin led to abnormality in paws and limbs, increased pressure in the eyes, blindness and animal death (in about 75% of the animals under study). Moreover, celecoxib and its combination with doxorubicin significantly increased cardiotoxicity biomarkers, oxidative stress markers (GSH and MDA), and mitochondrial toxicity parameters (SDH, ROS formation, MMP collapse, mitochondrial swelling). However, the combination of vitamin D with celecoxib and celecoxib + doxorubicin caused a significant reversal of deformity in paws and limbs, increased pressure in the eye, blindness, and animal death, as well as cardiotoxicity, oxidative stress, and mitochondrial parameters. This study proved for the first time the beneficial effect of vitamin D on celecoxib-induced cardiotoxicity, which is aggravated in the presence of doxorubicin through the maintenance of mitochondrial functions and its antioxidant potential.
The onset and progression of periodontitis involves complicated interactions between the dysbiotic oral microbiota and disrupted host immune-inflammatory response, which can be mirrored by the changes in salivary metabolites profile. This pilot study sought to examine the saliva microbiome and metabolome in the Chinese population by the combined approach of 16s rRNA sequencing and high-throughput targeted metabolomics to discover potential cues for host-microbe metabolic interactions. Unstimulated whole saliva samples were collected from eighteen Stage III and IV periodontitis patients and thirteen healthy subjects. Full-mouth periodontal parameters were recorded. The taxonomic composition of microbiota was obtained by 16s rRNA sequencing, and the metabolites were identified and measured by ultra-high performance liquid chromatography and mass spectrometry-based metabolomic analysis. The oral microbiota composition displayed marked changes where the abundance of 93 microbial taxa differed significantly between the periodontitis and healthy group. Targeted metabolomics identified 103 differential metabolites between the patients and healthy individuals. Functional enrichment analysis demonstrated the upregulation of protein digestion and absorption, histidine metabolism, and nicotinate and nicotinamide metabolism pathways in the dysbiotic microbiota, while the ferroptosis, tryptophan metabolism, glutathione metabolism, and carbon metabolism pathways were upregulated in the patients. Correlation analysis confirmed positive relationships between the clinical parameters, pathogen abundances, and disease-related metabolite levels. The integral analysis of the saliva microbiome and metabolome yielded an accurate presentation of the dysbiotic oral microbiome and functional alterations in host-microbe metabolism. The microbial and metabolic profiling of the saliva could be a potential tool in the diagnosis, prognosis evaluation, and pathogenesis study of periodontitis.
This is a prospective, single-center, randomized controlled trial. In this part,a total of 90 patients with paroxysmal atrial fibrillation who are scheduled for catheter ablation were randomly divided into 3 groups, 30 patients in each group. For the first group, the AI target value for the front wall and the top wall is 550, and the rear wall and the lower wall are 400. For the second group, the AI target values for the front wall and the top wall are 500, the rear wall and the lower wall are 350. For the third group, the AI target values for the front wall and top wall are 450, the rear wall and the lower wall are 300. The pressure value at each point is 5-15 g, and the distance between adjacent ablation points is less than 5 mm. The relevant indicators such as single-circle isolation rate of the pulmonary vein, operation time, the left atrial operation time, and the supplemental ablation site are recoded. The incidence of intraoperative and postoperative complications such as stroke, pericardial tamponade and steam pop during ablation are observed. Dynamic electrocardiography is performed during the follow-up period to evaluate the proportion of sinus rhythm within 1 year.
The invention discloses a patch for children with acute diarrhea. The patch for children with acute diarrhea comprises the following raw materials: root of chinese barberry, coptis chinensis, golden cypress, gallnut, fresh ginger, agastache rugosus and rhizoma atractylodis. The invention discloses a method for preparing the patch for children with acute diarrhea. The method comprises the following steps: cutting the root of Chinese barberry, the coptis chinensis and the golden cypress into small segments; adding 5-8fold water, heating to 60-70 DEG C, and carrying out reflux extraction once; filtering to obtain filtrate; adding an ethanol solution to filter residues; carrying out reflux extraction once, and filtering to obtain filtrate; merging filtrate of twice for later use; putting the gallnut, the fresh ginger, the agastache rugosus and the rhizoma atractylodis into a steam box to steam, wherein the temperature achieves 95-100 DEG C, and the time is 2-3 hours; repeatedly steaming for 2-3 times; finally collecting water vapor; adding to a concentrating pot to concentrate at high temperature after merging the filtrate with water vapor to obtain the patch body. The patch can be independently applied to treatment of noninfectious diarrhea in children caused by cold and dyspepsia, the effective components in the patch, such as the coptis chinensis and the golden cypress can be used for tonifying the spleen and warming the middle warmer, and dispelling cold and stopping diarrhea, and the gallnut can be used for astringing the lung. Therefore, the patch is good in effect.